General Mills Charts a New Course Amid Profit Pressures

General Mills shifts strategy toward protein and fiber-rich foods as weight-loss drugs change consumer habits, aiming to counter a steep earnings decline and falling stock price.

The American food conglomerate General Mills is navigating a period of significant earnings decline and missed market expectations. As its traditional business segments face pricing challenges and waning consumer demand, company leadership is pivoting its strategy toward a specific market niche. Ironically, the surge in popularity of modern weight-loss drugs is providing a potential catalyst for revitalizing its product portfolio.

Strategic Shift Toward Functional Nutrition

In response to the ongoing downturn, General Mills is actively reshaping its brand lineup. The strategic emphasis is increasingly moving toward protein-rich and health-conscious food options. This includes expanding the Cheerios Protein line and entering a collaboration with the brand Ghost to co-develop specialized cereals and snack bars.

An unexpected driver for this strategic realignment is shifting consumer behavior linked to GLP-1 agonist medications used for weight management. Users of these drugs frequently require diets higher in fiber. According to the company, this trend is already fueling increased demand for products under its Fiber One brand. Concurrently, the Nature Valley snack line is proving to be a resilient performer within the broader assortment.

For investors, the company's relatively high dividend yield currently offers a financial buffer against persistent share price depreciation. The success of this strategic pivot into functional nutrition will be measured in the coming months by the sales performance of the repositioned brands. The upcoming release of annual results this summer will provide the next critical data point for assessing this transformation.

A Detailed Look at the Financial Performance

The most recent quarterly figures, reported in March, clearly outline the current challenges. The company posted an 8% decline in revenue, while its adjusted earnings per share fell by 37% on a constant-currency basis, missing Wall Street estimates. The outlook for the fiscal year ending in May 2026 offers little cause for optimism: management anticipates a further profit decline in the range of 16 to 20%.

This sustained downward pressure is mirrored in the stock's performance. Year-to-date, the shares have declined by approximately 42%. In recent trading, the stock closed at €31.70, hovering just above its current 52-week low.

Market analysts were quick to react to the subdued prospects. UBS lowered its price target to $35, citing a difficult operating environment where near-term sales growth appears unlikely. RBC Capital Markets also reduced its target, moving from $60 to $55, while maintaining its "Outperform" rating on the equity.